Ir Immune Defic Syndr. Author manuscript; available in PMC 2013 June 01.Mosam et al.Pagena e, 89 had advanced (but not immediately life threatening) KS and 58 had CD4
Ir Immune Defic Syndr. Author manuscript; available in PMC 2013 June 01.Mosam et al.Pagena e, 89 had advanced (but not immediately life threatening) KS and 58 had CD4
Amic changes in conformation and function of the HIV-1 envelope glycoproteins, immediately after engagement of the activating molecules. Using these tools, we found that SCMs inactivate envelope glycoprotein function by an activation-triggered inhibition process, through induction of a metastable activated state.Materials and Methods Reagents and AntibodiesFour-domain sCD4 (molecular weight 50 kDa
To current convention [46]). C34-Ig was produced and purified as previously described [47]. The CD4-Ig fusion protein consists of the first two N-terminal domains of the CD4 molecule and the Fc region of human IgG1. Purification was carried out as described for the C34-Ig molecule [47].mechanism of sCD4 neutralization [17,18]. Resistance to sCD4 may thus arise by a decreased affinity of the envelo
He N-terminal residue of gp41) using the overlapping PCR method.Cell-Based Enzyme-Linked Immunosorbent Assay (ELISA)A sensitive cell-based ELISA with high temporal resolution was developed to measure the binding of antibodies to HIV-1 envelopeMetastable Activation of HIV-1 Envglycoprotein trimers expressed on cells. COS-1 cells were seeded in 96-well plates (2.46104 cells per well) and transfected
Ied [31,32]. These compounds, which include the prototypic compound NBD556 and its derivatives, mimic the effects of CD4 by inducing the exposure of the coreceptor-binding site on gp120 [31,33]. Although NBD-556 inhibits HIV-1 infection of CD4+CCR5+ cells, it can replace CD4 and thus enhance HIV-1 infection of CD42CCR5+ cells [31]. In view of their capacity to enhance infectivity, any potential ap
Ied [31,32]. These compounds, which include the prototypic compound NBD556 and its derivatives, mimic the effects of CD4 by inducing the exposure of the coreceptor-binding site on gp120 [31,33]. Although NBD-556 inhibits HIV-1 infection of CD4+CCR5+ cells, it can replace CD4 and thus enhance HIV-1 infection of CD42CCR5+ cells [31]. In view of their capacity to enhance infectivity, any potential ap
Port, we show that soluble mimics of CD4 inhibit HIV-1 infection by prematurely triggering the viral envelope glycoproteins. The unstable activated state of the virus lasts only a few minutes, after which the virus loses the ability to infect cells. This novel strategy for inhibition may be generally applicable to other viruses besides HIV-1, some of which are also activated by binding to their re